Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT

Chronic Active Epstein-Barr Virus Infection Clinical Trial

Official title:
Clinical Study on the Efficacy and Safety of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-associated Hemophagocytic Lymphohistiocytosis After Allogeneic Hematopoietic Stem Cell Transplantation

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of donor EBV-specific T lymphocytes (EBV-CTL) infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Clinical Trial Description

Evaluate the efficacy and safety of donor EBV-specific T lymphocytes (EBV-CTL) infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) ;

Study Design

Related Conditions & MeSH terms

Chronic Active Epstein-Barr Virus Infection
Epstein-Barr Virus Infections
Lymphohistiocytosis, Hemophagocytic
Virus-Associated Hemophagocytic Syndrome

Clinical Trial Details

NCT number	NCT05532826
Study type	Interventional
Source	Beijing Friendship Hospital
Contact	zhao wang, MD
Phone	86010631383803
Email	wangzhao@ccmu.edu.cn
Status	Recruiting
Phase	N/A
Start date	October 8, 2022
Completion date	September 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05841342` - Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
Recruiting	`NCT05384743` - Rituximab Monotherapy for EBV-HLH and CAEBV	Phase 3
Completed	`NCT01998633` - Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)	Phase 2